Published on : Mar 17, 2017
ALBANY, NY, March 17, 2017: The U.K. proton therapy market is prognosticated to run a course of upward growth with an increasing number of centers expected to be established in the not-so-distant future. In a report, titled “United Kingdom (UK) Proton Therapy Market, Reimbursement Policy, Patients Treated at Proton Facility & Forecast,” included by ResearchMoz.us in its Therapeutic Area archive, the market is anticipated to put on record a staggering 82.0% CAGR in the foreseeable future.
One of the most interesting findings of this report is the 10 times more growth expected on the part of the U.K. proton therapy market from what it had attained in 2016. Another aspect that testifies for this titanic growth of the market is the drastic change predicted to take place in the backdrop of six proton therapy centers prophesied to be built in the next few years.
Currently, there is only one facility operating in the country, which is actually a low energy equipment installed in the Clatterbridge Cancer Centre. This machine is researched to be only applicable for rare eye cancer treatments. However, with the course of time, the U.K. will have its own facility centers to treat patients with high energy beam therapies, such as proton, cancelling the need to visit Switzerland or the U.S. for treatment. In most cases, presently, the National Health Service (NHS) bears the expense of sending complex cancer patients to other countries for high-quality and sophisticated treatments.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=998975
Possessors of the publication will have access to a key analysis performed for studying the revenue scenario of three prominent players, viz. Elekta, Varian Medical Systems, and IBA Proton Therapy. Besides providing a broad overview of the aforementioned companies, the analysts have made available a profound evaluation of their sales. The company analysis section includes market figures from 2010 to 2021.
Players in the U.K. proton therapy market could face a couple of challenges, i.e. operational difficulty and enormous investment requirement, according to the report. Howbeit, the market also offers opportunities for players to keep their heads up in the face of these challenges. Unfortunately, the number of cancer patients in the U.K. is growing at a decent pace. In this regard, the market is envisaged to draw in a high degree of demand as patients prefer sophisticated and technologically advanced treatment options. Continuing with that, it is no wonder that any development in the proton therapy technology will help the market to progress further.
Apart from reimbursement policies for patients, manufacturers, stakeholders, and institutions, the U.K. proton therapy market report brings to light a study of the tapped and untapped markets for patients treated with the therapy. Buyers of the report are also provided with information on pipeline and operational proton therapy centers.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org